UPDATE: BofA/Merrill On Ultragenyx Says Following FDA Approval Of Burosumab, Firm Removes 'risk assumption for US sales in our model and now est. risk-adj. 2018 sales of $74mn'; Firm Had Previously Expected Sales Of $59M